Group 1 - The company, Dong'e Ejiao Co., Ltd., announced a share repurchase plan approved by its board of directors on December 4, 2025 [1] - The announcement includes details about the top ten shareholders and the top ten unrestricted shareholders, including their names, shareholdings, and proportions [1][2] - The shareholding data combines both ordinary accounts and margin trading accounts for accuracy [1][2] Group 2 - The company is complying with relevant regulations such as the "Listed Company Share Repurchase Rules" and the "Shenzhen Stock Exchange Self-Regulatory Guidelines No. 9" [1] - The shareholder register was provided by China Securities Depository and Clearing Corporation Limited, Shenzhen Branch [3] - The announcement was officially made by the company's board of directors on December 12, 2025 [5]

Core Viewpoint - The company has outlined a shareholder dividend return plan for the years 2025 to 2027, aiming to establish a scientific, sustainable, and stable return mechanism for investors [1] Group 1 - The company emphasizes the importance of shareholder interests and is committed to creating sustainable and reasonable long-term value for investors through prudent operations and a clear return plan [1]

Core Viewpoint - The company emphasizes that its stock price is influenced by multiple market factors, including industry policies, market liquidity, and investor preferences, and encourages a rational approach to market fluctuations [2] Company Operations - The company confirms that its production and operations are currently normal and will continue to focus on its development strategy and operational goals [2] - The operational strategy includes strengthening its formulation, optimizing its herbal pieces, refining research and development, and expanding into traditional Chinese medicine [2] - The company aims to balance quality and efficiency while enhancing internal quality and strengthening management and core competitiveness to promote high-quality development and value enhancement [2]

Core Viewpoint - Xinguang Pharmaceutical (300519) has announced that its new drug "YHTKL" has completed the basic research of prescriptions and is now entering the stage of process and quality standard research [1] Group 1 - The company has responded to investor inquiries on its interactive platform regarding the progress of its new drug [1] - The new drug "YHTKL" is currently in the process of developing its quality standards [1]

证券日报网讯 12月11日，东阿阿胶在互动平台回答投资者提问时表示，公司始终高度重视股东回报， 并保持相对稳定且积极的分红政策。未来，公司将在综合考虑自身经营发展规划、盈利水平、现金流状 况以及股东利益等多方面因素的基础上，有序推进分红政策进一步制度化，以增强回报的稳定性和可预 期性。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 12月11日，益盛药业在互动平台回答投资者提问时表示，截至2025年12月10日，公司股 东总户数为27186户。 ...

证券日报网讯 12月11日，东阿阿胶在互动平台回答投资者提问时表示，截至2025年11月10日，公司股 东总数为96750户。 （文章来源：证券日报） ...

Group 1 - The company will maintain a dynamic balance between product sales and prices, with no plans to adjust product prices in the short term [1] - The company aims to develop new products centered around consumer demand, including series like "Ejiao +" and "Ejiao", to explore new business growth points [1] - The focus is on promoting sustainable high-quality development through these initiatives [1] Group 2 - An investor inquired about potential adjustments to the average price of core products by 2025 and the company's strategy preference between maintaining sales and stabilizing prices [3]

Core Viewpoint - The "Double Dragon Mark" of Tongrentang serves as a symbol of authenticity and quality assurance for consumers, representing over 300 years of traditional Chinese medicine culture [1][4]. Group 1: Brand Significance - The "Double Dragon Mark" was created in 1980 by designer Zhuang Shuying and has become a renowned trademark both domestically and internationally [4]. - The design of the mark incorporates elements from traditional Chinese culture, including a circular layout inspired by the classic wax-sealed big honey pill, symbolizing product quality and harmonious formulation [4]. - The mark features the calligraphy of famous calligrapher Qi Gong, emphasizing the cultural heritage of the brand [4]. Group 2: Brand Protection and Quality Assurance - The "Double Dragon Mark" is the only legally held core brand identifier by Tongrentang Group, symbolizing the exclusive inheritance of the "Tongrentang" name [4]. - According to brand management rules, no individual or entity may use any form of the "Tongrentang" name or related symbols without written authorization from the group [4]. - The mark reflects the company's commitment to quality control and production processes, adhering to the ancient principle of meticulous craftsmanship [4]. Group 3: Consumer Guidance - Consumers are advised to look for the "Double Dragon Mark" on product packaging to ensure they are purchasing authentic Tongrentang products, whether online or in physical stores [5]. - The mark serves as a direct symbol for identifying genuine products and represents Tongrentang's promise of quality to consumers, safeguarding the brand's reputation [5].

Investment Rating - The report assigns a "Buy" investment rating to the company [2][6]. Core Insights - The company has completed adjustments in its governance structure and management team, marking a new development phase and focusing on high-quality growth [5][14]. - The company reported a significant increase in net profit for Q3 2025, with a year-on-year growth of approximately 29% [31]. - The dividend payout ratio is set to increase to 46% in 2024, with corresponding increases in dividend yields for both A-shares and H-shares [5][35]. Summary by Sections Governance Changes and Strategic Focus - The company has completed the adjustment of its senior management team, with new leadership expected to enhance operational quality [16][30]. - The new governance structure emphasizes internationalization, digital transformation, and innovation in research and development [30]. - The company is advancing its strategic planning for the "15th Five-Year Plan" while ensuring the completion of the "14th Five-Year Plan" [37][38]. Business Performance - The commercial segment remains a cornerstone of revenue, with a compound annual growth rate (CAGR) of approximately 6% from 2020 to 2024 [15][39]. - The traditional Chinese medicine segment is under short-term pressure, with a decline in revenue due to inventory adjustments and increased competition [15][41]. - The health segment is experiencing growth, with a revenue increase of over 7% in the first half of 2025 [15][45]. Financial Projections - Revenue projections for 2025-2027 are estimated at 790.01 billion, 840.61 billion, and 894.5 billion respectively, with corresponding net profits of 37.35 billion, 39.63 billion, and 44.27 billion [6][7]. - The company anticipates a net profit growth of approximately 31.7% in 2025, followed by more moderate growth in subsequent years [6][7]. Dividend Policy - The company plans to increase its dividend payout ratio to 46% in 2024, significantly higher than the 30% range maintained from 2019 to 2023 [5][35]. - The expected dividend yield for A-shares is approximately 2.81%, while H-shares are projected to yield around 4.83% [5][35].